Inclusion Criteria:

- Patients must have their pathology reviewed and the diagnosis confirmed.

- Performance status must be CALGB PS 0, 1, or 2

- Patients must have a 3-5/6 HLA-matched related donor who is evaluated and deemed able
to provide PBPCs and/or marrow by the transplant team.

- HIV antibody negative.

- Patients must test negative serum beta-HCG and must agree to use some form of
adequate birth control during the periods they receive chemotherapy and any
post-chemotherapy medications related to the transplant.

- Patients must be 17 years of age or greater.

- Patients must also have a resting MUGA and/or ECHO and PFTs with DLCO performed
before transplant and found to be acceptable according to the treating institution's
guidelines. The required minimum standards include MUGA and/or ECHO showing an EF of
40% and PFTs showing DLCO of 40%. Those with an EF 40-50%, undergo cardiac evaluation
and consultation. Also, those with DLCO 40-50%, undergo pulmonary evaluation and
consultation.

- Specific populations for each disease category:

- Hematologic malignancies Those with high risk or relapsed hematologic malignancy
(including myeloid and lymphoid leukemias and lymphomas, myeloma or myelomatous
like diseases, myeloproliferative disease, myelodysplasia). Those with good risk
disease (first remission AML with inv 16 M4 Eos, M3 AML with t(15;17); or
t(8;21) in first remission are not eligible).

- Bone marrow failure:

- Those specifically with idiopathic or secondary moderate, severe or very
severe aplastic anemia (idiopathic or secondary) according to the accepted
'Camitta criteria' would be candidates.

- Those with diseases known to lead to severe marrow failure are eligible as
well. These include those with myelofibrosis or PNH.

- Solid Tumors:

- Patients must have had a biopsy confirming disease recurrence (metastases)
at some point in their history, unless the patient presented with
metastatic disease, in which case the initial primary site biopsy is
adequate.

- Patients with renal cell cancer, or melanoma will be eligible for this approach at
this time. Patients will have had documented metastatic disease at some time in the
past. Patients who are in remission or with residual disease after prior therapy for
their metastatic disease are eligible, as there is no accepted cure for these
patients with metastatic disease.

- Breast Cancer- Patients will have had documented metastatic disease at some time in
the past. Patients who are in remission or with residual disease after prior therapy
for their metastatic disease are eligible. Patient must have failed at least one
chemotherapy regimen for their metastatic disease and 1 hormonal agent if they are
receptor positive.

Exclusion Criteria:

- Pregnant or lactating women,

- Patients with other major medical or psychiatric illnesses which the treating
physician feels could seriously compromise tolerance to this protocol, and

- Leukemia patients in first remission with good risk cytogenetics for leukemia
[t(15;17); t(8,22)]